A young specialist explores a paradigm shift in the cyclical 'treat, respond, relapse, repeat' approach to therapy for ...

A rapidly developed, dual-target chimeric antigen receptor T-cell therapy produced a 100% overall response rate in patients ...

Long-term results of a phase 3 trial show that early rituximab monotherapy significantly delays the need for new treatment in ...

Prakash Patel is currently undergoing chemotherapy for follicular lymphoma cancer and unexpectedly had his Lloyds bank account closed.

Genmab Announces Financial Results for the First Quarter of 2024May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025HighlightsEPKINLY® (epcoritamab) approved by ...

Genmab (Nasdaq: GMAB) posted a 19% rise in revenue to $715 million for the first quarter of 2025, driven by higher royalties ...

Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025 Highlights EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional ...

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...